Details of the Drug
General Information of Drug (ID: DMI5R3E)
Drug Name |
(+/-)-oxiran-2-ylmethyl (9Z)-octadec-9-enoate
|
||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
Glycidyl oleate; Glycidol oleate; Oleic acid glycidyl ester; 2,3-Epoxypropyl oleate; Glycidyl octadecenoate; 5431-33-4; 2,3-Epoxy-1-propanol oleate; NSC 13542; 2,3-Epoxypropyl ester of oleic acid; Oxiranylmethyl ester of 9-octadecenoic acid; Oleic acid, 2,3-epoxypropyl ester; EINECS 226-588-0; Glycidylester kyseliny olejove [Czech]; AI3-03518; CHEMBL230967; CHEBI:82469; VWYIWOYBERNXLX-KTKRTIGZSA-N; 9-OCTADECENOIC ACID (Z)-, OXIRANYLMETHYL ESTER; Oxiranyl methyl ester 9-octadecenoic acid; 9-Octadecenoic acid (9Z)-, oxiranylmet
|
||||||||||||||||||||||
Indication |
|
||||||||||||||||||||||
Drug Type |
Small molecular drug
|
||||||||||||||||||||||
Structure | |||||||||||||||||||||||
3D MOL | 2D MOL | ||||||||||||||||||||||
#Ro5 Violations (Lipinski): 2 | Molecular Weight (mw) | 338.5 | |||||||||||||||||||||
Logarithm of the Partition Coefficient (xlogp) | 7.3 | ||||||||||||||||||||||
Rotatable Bond Count (rotbonds) | 18 | ||||||||||||||||||||||
Hydrogen Bond Donor Count (hbonddonor) | 0 | ||||||||||||||||||||||
Hydrogen Bond Acceptor Count (hbondacc) | 3 | ||||||||||||||||||||||
Chemical Identifiers |
|
||||||||||||||||||||||
Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
The Studied Disease | Discovery agent | |||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ICD Disease Classification | N.A. | |||||||||||||||||||||||
|
||||||||||||||||||||||||
Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||